Form 4: Xeris Biopharma Director Sells 15,500 Shares

Xeris Biopharma Holdings Director Marla Persky sold 15,500 shares of common stock at a weighted average price of $7.7168 per share under a Rule 10b5-1 trading plan.

Summary

• Director Marla Persky sold 15,500 shares of Xeris Biopharma Holdings, Inc. common stock.
• The transaction occurred on September 11, 2025.
• The shares were sold at a weighted average price of $7.7168, with individual sales ranging from $7.650 to $7.840.
• This sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, Marla Persky directly owns 142,000 shares and indirectly owns 6,370 shares through a revocable trust.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even under a 10b5-1 plan, generally carries a slightly negative sentiment as it reduces insider ownership. However, the pre-planned nature mitigates a strong negative reaction.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to new, non-public information.

Negatives

• A director reduced their direct ownership in the company by 15,500 shares.

Risks

• Potential negative investor sentiment due to an insider selling shares, even if pre-planned.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, which is typical for this document type.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Indirect beneficial ownership of 6,370 shares is held through the Marla Susan Persky Revocable Trust u/a dated 9/23/2000.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially influencing their investment decisions.

Key Dates

Recommendation

While a director's sale of shares can be a negative signal, the transaction was executed under a pre-arranged 10b5-1 plan, which suggests personal financial planning rather than a reaction to new, adverse company-specific information. Without additional context on the company's performance or other market factors, this single insider sale does not warrant a strong buy or sell recommendation, thus a 'hold' is appropriate.

Keywords

Xeris Biopharma Holdings, XERS, Insider Trading, Form 4, Director Sale, Marla Persky, 10b5-1 Plan, Biopharma, Stock Sale